联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4254人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313801, encodeId=e51f1313801b6, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JAHA：脂肪酸与强化他汀联合治疗对急性冠脉综合征患者冠脉斑块的影响, objectType=article, longId=198800, objectId=7b7419880066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7419880066, replyNumber=0, likeNumber=82, createdTime=2020-08-07, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7419880066, moduleTitle=JAHA：脂肪酸与强化他汀联合治疗对急性冠脉综合征患者冠脉斑块的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b7419880066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313800, encodeId=635c13138003e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=EUR HEART J-CARD PHA：与利尿剂和心率或心律控制药物联合治疗的房颤患者血清钾水平与短期死亡率的关系如何？, objectType=article, longId=198582, objectId=e1ef198582c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1ef198582c3, replyNumber=0, likeNumber=64, createdTime=2020-08-03, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1ef198582c3, moduleTitle=EUR HEART J-CARD PHA：与利尿剂和心率或心律控制药物联合治疗的房颤患者血清钾水平与短期死亡率的关系如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1ef198582c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313799, encodeId=f5a91313e99b9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=杨田教授：2020年版《CSCO原发性肝癌诊疗指南》更新要点解读，聚焦免疫靶向联合治疗, objectType=article, longId=198115, objectId=160f19811556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=160f19811556, replyNumber=0, likeNumber=80, createdTime=2020-07-28, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=160f19811556, moduleTitle=杨田教授：2020年版《CSCO原发性肝癌诊疗指南》更新要点解读，聚焦免疫靶向联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=160f19811556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313798, encodeId=07821313e98ef, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效, objectType=article, longId=198000, objectId=ff2a19800082, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff2a19800082, replyNumber=0, likeNumber=95, createdTime=2020-07-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff2a19800082, moduleTitle=Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff2a19800082)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313797, encodeId=37441313e9781, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征, objectType=article, longId=197791, objectId=327a19e79151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=327a19e79151, replyNumber=0, likeNumber=90, createdTime=2020-07-21, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=327a19e79151, moduleTitle=FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=327a19e79151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313796, encodeId=1a7e1313e967e, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=关于公开征求《抗肿瘤药联合治疗临床试验技术指导原则》意见的通知, objectType=article, longId=197705, objectId=a79a19e70511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a79a19e70511, replyNumber=0, likeNumber=77, createdTime=2020-07-19, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a79a19e70511, moduleTitle=关于公开征求《抗肿瘤药联合治疗临床试验技术指导原则》意见的通知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a79a19e70511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313795, encodeId=e9e21313e9598, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=遗传性牙龈纤维瘤病牙周-正畸联合治疗1例, objectType=article, longId=197679, objectId=f7f419e679b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7f419e679b9, replyNumber=0, likeNumber=74, createdTime=2020-07-19, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7f419e679b9, moduleTitle=遗传性牙龈纤维瘤病牙周-正畸联合治疗1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7f419e679b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313794, encodeId=d5211313e94ce, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高, objectType=article, longId=197416, objectId=429719e4161f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=429719e4161f, replyNumber=0, likeNumber=68, createdTime=2020-07-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=429719e4161f, moduleTitle=危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=429719e4161f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313793, encodeId=98791313e937c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Am J Respir Crit Care Med：口服曲普司他尼联合治疗肺动脉高血压, objectType=article, longId=196508, objectId=dfa419650817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfa419650817, replyNumber=0, likeNumber=100, createdTime=2020-06-27, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfa419650817, moduleTitle=Am J Respir Crit Care Med：口服曲普司他尼联合治疗肺动脉高血压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfa419650817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313792, encodeId=bf921313e9231, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Lancet oncol：仑伐替尼和派姆单抗联合治疗晚期胃癌, objectType=article, longId=196409, objectId=534919640909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=534919640909, replyNumber=0, likeNumber=71, createdTime=2020-06-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=534919640909, moduleTitle=Lancet oncol：仑伐替尼和派姆单抗联合治疗晚期胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=534919640909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313791, encodeId=06c51313e917a, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Sci Rep：一个用于鉴定联合治疗有效性的QSP前列腺癌免疫治疗模型 , objectType=article, longId=196403, objectId=b7b71964033b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7b71964033b, replyNumber=0, likeNumber=76, createdTime=2020-06-26, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7b71964033b, moduleTitle=Sci Rep：一个用于鉴定联合治疗有效性的QSP前列腺癌免疫治疗模型 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7b71964033b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313790, encodeId=1c0f1313e9006, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗, objectType=article, longId=196066, objectId=8dab1960666a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dab1960666a, replyNumber=0, likeNumber=84, createdTime=2020-06-19, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dab1960666a, moduleTitle=FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dab1960666a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313789, encodeId=29081313e896b, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=中风患者的福音！联合治疗能够恢复中风患者的认知能力且延长治疗窗口期, objectType=article, longId=195554, objectId=bcc2195554ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcc2195554ad, replyNumber=0, likeNumber=90, createdTime=2020-06-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcc2195554ad, moduleTitle=中风患者的福音！联合治疗能够恢复中风患者的认知能力且延长治疗窗口期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcc2195554ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, objectType=article, longId=195394, objectId=51fd195394e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51fd195394e1, replyNumber=0, likeNumber=60, createdTime=2020-06-07, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51fd195394e1, moduleTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51fd195394e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313787, encodeId=01ad1313e87f9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动, objectType=article, longId=193667, objectId=9ff219366ee3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ff219366ee3, replyNumber=0, likeNumber=79, createdTime=2020-05-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ff219366ee3, moduleTitle=抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ff219366ee3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313786, encodeId=5a501313e86f2, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月, objectType=article, longId=193174, objectId=9c411931e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c411931e4ea, replyNumber=0, likeNumber=73, createdTime=2020-05-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c411931e4ea, moduleTitle=AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c411931e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313785, encodeId=b20e1313e85bc, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Eur Respir J：贝达喹啉 VS贝达喹啉-达拉米尼联合治疗耐多药结核病的效果, objectType=article, longId=192363, objectId=4e1e19236383, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1e19236383, replyNumber=0, likeNumber=64, createdTime=2020-04-17, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1e19236383, moduleTitle=Eur Respir J：贝达喹啉 VS贝达喹啉-达拉米尼联合治疗耐多药结核病的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1e19236383)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313784, encodeId=bc721313e8408, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Rheumatol：银屑病关节炎中TNFi单药治疗与联合治疗的比较, objectType=article, longId=192087, objectId=6d0019208efd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d0019208efd, replyNumber=0, likeNumber=91, createdTime=2020-04-14, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d0019208efd, moduleTitle=J Rheumatol：银屑病关节炎中TNFi单药治疗与联合治疗的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d0019208efd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313783, encodeId=22aa1313e8375, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle= Eur Respir J：抗药性肺结核患者使用贝达奎林-达拉米尼联合治疗是否优于贝达奎林单药治疗的效果？, objectType=article, longId=191951, objectId=4482191951c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4482191951c9, replyNumber=0, likeNumber=80, createdTime=2020-04-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4482191951c9, moduleTitle= Eur Respir J：抗药性肺结核患者使用贝达奎林-达拉米尼联合治疗是否优于贝达奎林单药治疗的效果？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4482191951c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313782, encodeId=37e61313e82ec, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, objectType=article, longId=191946, objectId=1e43191946c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e43191946c0, replyNumber=0, likeNumber=57, createdTime=2020-04-11, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e43191946c0, moduleTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e43191946c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JAHA：脂肪酸与强化他汀联合治疗对急性冠脉综合征患者冠脉斑块的影响

2020-08-07

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

EUR HEART J-CARD PHA：与利尿剂和心率或心律控制药物联合治疗的房颤患者血清钾水平与短期死亡率的关系如何？

2020-08-03

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

杨田教授：2020年版《CSCO原发性肝癌诊疗指南》更新要点解读，聚焦免疫靶向联合治疗

2020-07-28

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Eur Respir J：吡非尼酮与吸入N-乙酰半胱氨酸联合治疗特发性肺纤维化疗效

2020-07-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征

2020-07-21

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

关于公开征求《抗肿瘤药联合治疗临床试验技术指导原则》意见的通知

2020-07-19

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

遗传性牙龈纤维瘤病牙周-正畸联合治疗1例

2020-07-19

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高

2020-07-14

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Am J Respir Crit Care Med：口服曲普司他尼联合治疗肺动脉高血压

2020-06-27

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Lancet oncol：仑伐替尼和派姆单抗联合治疗晚期胃癌

2020-06-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Sci Rep：一个用于鉴定联合治疗有效性的QSP前列腺癌免疫治疗模型

2020-06-26

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗

2020-06-19

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

中风患者的福音！联合治疗能够恢复中风患者的认知能力且延长治疗窗口期

2020-06-11

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌

2020-06-07

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动

2020-05-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月

2020-05-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Eur Respir J：贝达喹啉 VS贝达喹啉-达拉米尼联合治疗耐多药结核病的效果

2020-04-17

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Rheumatol：银屑病关节炎中TNFi单药治疗与联合治疗的比较

2020-04-14

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Eur Respir J：抗药性肺结核患者使用贝达奎林-达拉米尼联合治疗是否优于贝达奎林单药治疗的效果？

2020-04-11

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌

2020-04-11

科室
- - 订阅+
  - 更多科室
工具
服务